MiNK Therapeutics Presents Novel Immunotherapy Approach at ATS 2026

Got story updates? Submit your updates here. ›

MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ATS International Conference 2026 in Orlando, Florida. The abstract highlights a novel combination approach leveraging immune activation and restoration to treat severe and persistent Coccidioides immitis infections.

Why it matters

MiNK's proprietary iNKT cell therapy platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. This presentation at the prestigious ATS conference showcases the potential of agenT-797 to address unmet needs in treating rare and difficult-to-treat infections.

The details

The abstract, titled 'Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy for Unresolving Coccidioides immitis Infection,' will be presented by Terese Hammond, MD. The presentation will highlight how the combination of MiNK's allogeneic iNKT cell therapy and an IL-15 superagonist can leverage immune activation and restoration to combat severe fungal infections.

• The ATS International Conference 2026 will take place from May 15-20, 2026 in Orlando, Florida.
• The abstract presentation is scheduled for Wednesday, May 20, 2026 from 11:00 AM to 1:00 PM EDT.

What’s next

The full details of the novel combination immunotherapy approach will be presented at the ATS International Conference 2026 in Orlando, Florida.